JOURNAL OF INTERNATIONAL CRISIS AND RISK COMMUNICATION RESEARCH
ISSN: 2576-0017
2024, VOL 7, NO S7

Identification of Novel Biomarkers for Early Diagnosis of Autoimmune Diseases: Review

Sara Selmi Alalwani[1], Tariq Bakr Atitullah Alharbi[2], Ghada Omar Almasmoum[3], Rawan Mohammed Alsuwat[4], Rawan Fahad Alomani[5], Bashaer Hamod Saad Alotaibi[6], Rana Salem Altalhi[6], Ahmad Essa Alotaibi[7], Abdulrahman Raja Alnefaie[8], Dareen Yassir Makki[9], Smaher Faisal Alsharif[9], Jihan Mohammed Ghurayba[9], Manal Saeed Bugshan[10], Abeer Hameed Salem[9], Ohoud Esam Moamena[11]

1. Mawqaq general hospital, Specialist laboratory
2. Laboratory Technician, Wadi Al-Faraa General Hospital, Madinah city
3. Lab specialist, King abdlaziz hospital in Makkah
4. Lab specialist, Regional Laboratory in Taif
5. Lab specialist, Children Hospital in Taif
6. Medical laboratory specialist, Children Hospital in Taif
7. Al-Khasra General Hospital, Laboratory technician
8. Al-Sahn Hospital, laboratory technician
9. Laboratory specialist, King Fahd general hospital jeddah
10. Laboratory technician, King Fahd general hospital jeddah
11. Health Monitoring Centers at King Abdulaziz International Airport in Jeddah, Medical Laboratory Technician

ABSTRACT

Autoimmune diseases (AIDs) are complex disorders characterized by immune system dysregulation, often progressing silently before clinical symptoms appear. Early diagnosis is critical to prevent irreversible tissue damage and improve outcomes, but current diagnostic tools lack sensitivity and specificity for detecting preclinical stages. Advances in genomics, proteomics, metabolomics, and microbiomics have identified promising biomarkers, including genetic variants (e.g., HLA-DR4), autoantibodies (e.g., anti-CarP), cytokines (e.g., IL-6, TNF-α), and microRNAs (e.g., miR-155). These biomarkers enhance diagnostic precision, enable early intervention, and support personalized medicine. However, challenges such as disease heterogeneity, validation gaps, and implementation barriers persist. Addressing these issues through standardization, multi-omics integration, and global collaboration can unlock the full potential of biomarkers, transforming the early diagnosis and management of autoimmune diseases.

1. Introduction

Autoimmune diseases (AIDs) are a diverse group of chronic disorders characterized by an immune system that mistakenly attacks the body's own tissues. Examples include rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), type 1

diabetes (T1D), multiple sclerosis (MS), and celiac disease. Together, these conditions affect millions worldwide and are a leading cause of morbidity. Despite their impact, the precise etiology of autoimmune diseases remains poorly understood, with complex interactions between genetic predisposition, environmental triggers, and immune dysregulation playing critical roles in disease development (1).

One of the significant challenges in managing autoimmune diseases is their insidious onset, with symptoms often appearing after considerable tissue damage has occurred. Early intervention is crucial to prevent irreversible damage, slow disease progression, and improve outcomes. However, early diagnosis is frequently hindered by the lack of sensitive and specific diagnostic tools capable of detecting the disease in its preclinical stages. Current diagnostic methods, such as the use of anti-nuclear antibodies (ANA) for SLE or rheumatoid factor (RF) for RA, suffer from limitations including low specificity, variability across populations, and delayed appearance in disease progression. Consequently, there is a pressing need for novel biomarkers that can provide reliable and early diagnostic insights into autoimmune diseases (2).

A biomarker is defined as a measurable indicator of a biological process, condition, or disease. In the context of autoimmune diseases, biomarkers can facilitate early diagnosis, stratify patients by disease severity, predict outcomes, and monitor treatment response. With advancements in technologies like genomics, proteomics, metabolomics, and microbiomics, the identification of novel biomarkers has expanded significantly. For example, genome-wide association studies (GWAS) have uncovered genetic variants linked to autoimmune susceptibility, while proteomic studies have highlighted cytokines and chemokines as early markers of inflammation. These innovations offer unprecedented opportunities to improve our understanding of autoimmune pathogenesis and enhance diagnostic precision (3,4).

This review explores the emerging landscape of novel biomarkers for autoimmune diseases, with a focus on their potential for early diagnosis. Key categories discussed include genetic markers, autoantibodies, proteomic profiles, metabolomic changes, microRNAs (miRNAs), and gut microbiome alterations. It also highlights the challenges associated with biomarker discovery, including disease heterogeneity, validation requirements, and integration into clinical workflows. Finally, the review considers future directions in biomarker research, emphasizing the role of multi-omics approaches and artificial intelligence in advancing early detection and personalized medicine for autoimmune diseases. By addressing these critical areas, this review aims to shed light on the transformative potential of biomarkers in improving outcomes for patients with autoimmune diseases.

2. Review:

1. Genetic Biomarkers

1.1. HLA Variants

The Human Leukocyte Antigen (HLA) system is one of the most well-studied

genetic contributors to autoimmune diseases. Variations in HLA genes are critical determinants of susceptibility in diseases such as rheumatoid arthritis (RA), type 1 diabetes (T1D), and celiac disease.

- HLA-DR and HLA-DQ Alleles:

HLA-DR4 is linked to RA, particularly in seropositive patients. Its presence has been associated with severe disease courses and early onset (1). HLA-DQ2 and HLA-DQ8 are almost universal in celiac disease and are useful for identifying individuals at genetic risk, even in the absence of clinical symptoms (2). In T1D, HLA-DR3/4 heterozygosity is associated with the highest genetic risk for disease development.

1.2. Non-HLA Genes

Genome-wide association studies (GWAS) have identified several non-HLA genes associated with autoimmune diseases:

- PTPN22:

This gene encodes a phosphatase that regulates T-cell signaling. A polymorphism in PTPN22 (R620W) has been implicated in RA, SLE, and T1D, increasing immune reactivity (3).

- IL2RA:

Polymorphisms in IL2RA, encoding the IL-2 receptor alpha chain, are associated with MS and T1D. Dysregulation of IL-2 signaling affects T regulatory cell function, contributing to autoimmunity (4).

1.3. Clinical Application

Genetic biomarkers are useful for risk prediction, particularly in individuals with a family history of autoimmune diseases. For example:

HLA typing is used to identify individuals at risk for celiac disease and guide preventive strategies, such as early dietary modifications. HLA-DQ2/DQ8 in Celiac Disease, these HLA alleles are present in over 95% of individuals with celiac disease, making them highly predictive markers, especially in asymptomatic individuals with a family history (2).

2. Autoantibody Biomarkers

Autoantibodies remain central to the diagnosis of many autoimmune diseases, but novel discoveries are enhancing their utility for early detection.

2.1. Novel Autoantibodies

- Anti-Carbamylated Protein (Anti-CarP) Antibodies:

o Present in a subset of RA patients, these antibodies can be detected even in seronegative cases and appear years before clinical symptoms, broadening the diagnostic window (5).

- Anti-Ro/SSA and Anti-La/SSB Antibodies:

o These are classic markers for Sjögren’s syndrome but are also predictive of

complications like neonatal lupus in pregnancies (6).

2.2. Autoantibody Profiles

Advances in multiplex autoantibody assays allow simultaneous detection of multiple antibodies, increasing diagnostic accuracy. For example:

- Combining RF, ACPA, and anti-CarP antibodies improves the sensitivity and specificity of RA diagnosis (7).

3. Proteomic Biomarkers

Proteomics enables the large-scale identification of protein signatures linked to immune activation and early autoimmune processes.

3.1. Cytokines and Chemokines

Cytokines are critical regulators of immune responses and inflammation. Elevated levels of certain cytokines are observed in preclinical autoimmune states:

- IL-6: Associated with synovial inflammation in RA, IL-6 levels can predict disease onset before radiological changes occur (8). Elevated in RA and MS, IL-6 is a key driver of inflammation and joint destruction. Its levels correlate with disease activity and may predict onset in high-risk individuals (8).

- TNF-α: Plays a central role in inflammatory pathways in RA and Crohn's disease. Its measurement is useful for identifying at-risk individuals (9).

- CXCL10 (IP-10): Elevated in preclinical lupus nephritis, it can serve as an early marker for renal involvement (10).

3.2. Complement System

- C3 and C4 Levels: Low complement levels are traditionally associated with active SLE but may also indicate subclinical disease activity.

- C3d: A product of complement activation, elevated levels correlate with early lupus onset (11).

4. Metabolomic Biomarkers

Metabolomics captures small-molecule profiles in biological fluids, providing insights into biochemical changes associated with autoimmune disease development.

4.1. Lipidomics

- Ceramides: Elevated ceramide levels are observed in lupus and MS, reflecting oxidative stress and cell apoptosis.

4.2. Amino Acid Pathways

- Tryptophan Metabolism: Disruptions in the kynurenine pathway, which regulates immune activation, are seen in RA and SLE. Kynurenine-to-tryptophan ratios are being explored as early diagnostic markers (12).

5. MicroRNA Biomarkers

MicroRNAs (miRNAs) regulate gene expression and are implicated in autoimmune disease pathogenesis.

5.1. Disease-Specific miRNAs

- miR-155 and miR-146a: Dysregulation of these miRNAs contributes to inflammation in RA, SLE, and MS. Their presence in circulating blood makes them accessible diagnostic tools (13).

6. Gut Microbiome Biomarkers

Gut dysbiosis, or an imbalance in microbial composition, has been linked to autoimmune disease onset.

6.1. Microbial Shifts

- Prevotella copri: Overrepresentation of this bacterium in the gut microbiota has been associated with early-stage RA (14).

6.2. Short-Chain Fatty Acids (SCFAs)

- SCFAs, such as butyrate, produced by gut bacteria, regulate immune homeostasis. Low SCFA levels are observed in MS and lupus patients, potentially serving as biomarkers (15).

7. Challenges in Biomarker Development

Despite significant advances in identifying novel biomarkers for autoimmune diseases (AIDs), their translation into clinical practice faces several challenges. These challenges stem from the inherent complexity of autoimmune diseases, technical limitations in biomarker discovery and validation, and logistical barriers to implementation in healthcare settings.

7.1. Disease Heterogeneity

Autoimmune diseases exhibit significant variability in clinical presentation, complicating the identification of universal biomarkers.

7.2. Validation and Standardization

Biomarkers require extensive validation across diverse populations to ensure reliability. For example, genetic and autoantibody markers identified in European populations may not translate to other ethnic groups (16).

8. Future Directions

Combining data from genomics, proteomics, and metabolomics can uncover complex interactions underlying autoimmune diseases, leading to more robust biomarkers.Bridging the gap between biomarker discovery and clinical application requires collaboration between researchers, clinicians, and industry stakeholders.

3. Discussion and Conclusion:

The identification of novel biomarkers has revolutionized the approach to early diagnosis in autoimmune diseases. Advances in genetics, proteomics, metabolomics, and immunology have unveiled promising candidates such as HLA alleles, anti-CarP antibodies, cytokines, and miRNAs. Despite challenges in validation and clinical implementation, these biomarkers hold immense potential for improving early detection, personalizing treatments, and enhancing patient outcomes. Continued investment in multi-omics research, global collaboration, and technological innovation will be critical to translating these discoveries into routine clinical practice. Despite these advancements, significant challenges remain in the development, validation, and integration of biomarkers into clinical practice. The heterogeneity of autoimmune diseases, variability in biomarker expression across populations and disease stages, and the lack of standardization in biomarker assays are major hurdles. Additionally, the high costs and technical complexities associated with biomarker testing, coupled with limited clinician awareness and training, hinder their widespread adoption. These issues are compounded by ethical concerns, including data privacy and the equitable access to biomarker technologies.

To overcome these challenges, future research must focus on validating biomarkers in diverse populations, standardizing testing protocols, and integrating multi-omics data to create robust diagnostic panels. The incorporation of artificial intelligence and machine learning can accelerate biomarker discovery and improve the predictive power of complex datasets. Additionally, fostering global collaboration and ensuring affordable, scalable testing methods are essential to making these innovations accessible to all patients, regardless of socioeconomic or geographic barriers.

Ultimately, the success of biomarker research will depend on a multidisciplinary approach that combines cutting-edge technology, rigorous validation, and strong healthcare infrastructure. By addressing the existing limitations and leveraging emerging opportunities, biomarkers can revolutionize the early diagnosis, management, and treatment of autoimmune diseases, paving the way for a new era of personalized medicine and improved patient care.

References

Ercolini AM, Miller SD. "The role of infections in autoimmune disease." Clinical and Experimental Immunology, 2009. DOI:10.1111/j.1365-2249.2009.04008.x.

Sollid LM, Jabri B. "Is celiac disease an autoimmune disorder?" Current Opinion in Immunology, 2005. DOI:10.1016/j.coi.2005.03.007.

Gregersen PK, Olsson LM. "Pathways to rheumatoid arthritis." Current Opinion in Immunology, 2009. DOI:10.1016/j.coi.2009.06.003.

Maier LM, Anderson DE. "Multiple sclerosis as a primary disorder of IL-2 signaling." Trends in Immunology, 2011. DOI:10.1016/j.it.2011.02.004.

Tsokos GC. "Systemic lupus erythematosus." New England Journal of Medicine, 2011. DOI:10.1056/NEJMra1100359.

Brink M, et al. "Anti-carbamylated protein antibodies in rheumatoid arthritis." Arthritis Research & Therapy, 2015. DOI:10.1186/s13075-015-0550-z.

Wahren-Herlenius M, Dorner T. "Immunopathogenic mechanisms of systemic autoimmune disease." The Lancet, 2013. DOI:10.1016/S0140-6736(13)60648-X.

Smolen JS, et al. "Rheumatoid arthritis." The Lancet, 2016. DOI:10.1016/S0140-6736(16)30173-8.

Feldmann M, Maini RN. "Role of TNF in the pathogenesis of rheumatoid arthritis and therapeutic implications." Annual Review of Immunology, 2001. DOI:10.1146/annurev.immunol.19.1.163.

Furie R, et al. "Novel biomarkers in systemic lupus erythematosus." Arthritis & Rheumatology, 2014. DOI:10.1002/art.38902.

Csuka D, et al. "Complement activation markers in systemic lupus erythematosus." Lupus, 2017. DOI:10.1177/0961203317701187.

Maceyka M, Spiegel S. "Lipid signaling in disease: Lipidomics sheds new light." Nature Reviews Drug Discovery, 2014. DOI:10.1038/nrd4271.

Yan D, et al. "The role of kynurenine pathway metabolites in autoimmune diseases." Mediators of Inflammation, 2015. DOI:10.1155/2015/205923.

Pauley KM, Cha S. "MicroRNA-146a in rheumatoid arthritis: Not all roads lead to resolution." Annals of the Rheumatic Diseases, 2011. DOI:10.1136/ard.2010.134668.

Dai R, Ahmed SA. "MicroRNA, a new paradigm for understanding immunoregulation, inflammation, and autoimmune diseases." Translational Research, 2011. DOI:10.1016/j.trsl.2011.01.007.

Scher JU, Abramson SB. "The microbiome and rheumatoid arthritis." Nature Reviews Rheumatology, 2011. DOI:10.1038/nrrheum.2011.121.